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1. Introduction 
Microvascular angina (MVA) is a form of ischemic heart disease (IHD) characterised by signs and symptoms of 
cardiac ischaemia triggered by coronary microvascular dysfunction (CMD).
1
 CMD, however, can also occur and 
play a pathogenic role in cardiac conditions other than MVA, i.e. hypertrophic cardiomyopathy (HCM) and 
aortic valve stenosis (AoS) which are also referred to as type 2 CMD.
3
 Moreover, CMD can be present in 
systemic conditions such as diabetes mellitus (DM), obesity, hypertensive pregnancy disorders (HPD), chronic 
inflammatory and auto-immune rheumatic disorders, and chronic kidney disease (CKD). Importantly, although 
CMD may not always cause symptoms of cardiac ischaemia in the setting of the cardiac and systemic conditions 
mentioned above, its presence has been shown to be consistently associated with adverse clinical outcomes.  
 
This review provides an overview of the pathogenic role of CMD in the setting of cardiac and systemic 
conditions other than MVA, and its clinical implications. We will describe the functional role of the coronary 
microcirculation in the delivery of blood for myocardial perfusion, and discuss the different conditions 
associated with CMD.  
  
Abstract  
Coronary microvascular dysfunction (CMD) plays a pathogenic role in cardiac and systemic conditions other  
than microvascular angina. In this review we provide an overview of the pathogenic role of CMD in the setting  
of diabetes mellitus, obesity, hypertensive pregnancy disorders, chronic inflammatory and autoimmune  
rheumatic disorders, chronic kidney disease, hypertrophic cardiomyopathy, and aortic valve stenosis. In these  
various conditions, CMD results from different structural, functional and/or dynamic alterations in the coronary  
microcirculation associated with the primary disease process. CMD is often detectable very early in the course  
of the primary disease, before clinical symptoms or signs of myocardial ischaemia are present, and it portrays  
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2. The role of the microvasculature in the coronary circulation 
In the coronary circulation, the resistance of the vascular components is coordinated by different regulatory 
mechanisms to match blood flow with oxygen requirements.
2, 4
 The large epicardial coronary arteries (500 µm 
– 5 mm in diameter) as well as the capillaries and venules act mainly as conductance vessels and offer very 
little resistance. The coronary blood flow is mainly controlled by the pre-arterioles and arterioles, also called 
the microvasculature. The epicardial pre-arterioles (100-500 µm in diameter) serve to maintain pressure within 
narrow limits at the origin of the arterioles and respond to flow-related stimuli with endothelium-dependent 
vasoreactivity. The intramyocardial arterioles (<100 µm in diameter) have the highest resistance and respond 
either by myogenic control or metabolites, differing per size.
5
 Myogenic control prevails in the medium-sized 
arterioles (40–100 µm in diameter), where stretch receptors in vascular smooth muscle cells (VSMCs) react to 
changes in pressure, high intraluminal pressure leads to vasoconstriction and vice versa. Control by metabolites 
prevails in the smaller arterioles (< 40 µm in diameter), in which an increased metabolic activity leads to 
vasodilatation. This leads to a reduction in pressure in the medium-sized arterioles, stimulating myogenic 
dilation and a subsequent increased flow upstream resulting in endothelium-dependent vasodilation in the 
pre-arterioles and epicardial coronary arteries. 
 
CMD can result in the inability of the coronary arteries to augment coronary blood flow (vasodilatory 
abnormality) and/or in a reduction in coronary blood flow (coronary microvascular spasm). CMD leading to 
ischaemia can occur in the absence and/or in the presence of obstructive epicardial coronary artery disease 
(CAD). CMD can be the consequence of an abnormal structure of the coronary microvasculature (e.g. intimal 
thickening, VSMC proliferation, low capillary density), a dynamic maldistribution of coronary blood flow often 
resulting from extra-coronary causes (e.g. short diastolic perfusion time) or compressive forces generated in 
the myocardium, or an abnormal coronary function (e.g. impaired vasodilatation by endothelial dysfunction), 
as depicted in figure 1.
6
 Endothelial dysfunction is defined as an imbalance between the release of 
vasoprotective vasorelaxant substances, such as nitric oxide (NO), prostacyclin (PGI2), endothelium-derived 
hyperpolarizing factors (EDHF), and pathological vasoconstricting substances, such as endothelin-1 (ET-1), 
superoxide, hydrogen peroxide, thromboxanes.
7
 While in large epicardial coronary arteries vasorelaxation is 
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2.1 Assessment of coronary microvascular function 
The diagnosis of CMD is established by functional assessment of the coronary arteries, which can be done by 
both invasive and non-invasive methods.
1, 9
 To assess endothelium-independent microvascular function, the 
coronary flow reserve (CFR) can be measured, which is defined by the rate of coronary blood flow at 
hyperaemia compared to baseline. The cut-off for an abnormal CFR is ≤2.5 or 2.0, depending on the technique 
that is being used.
1
 Another parameter that demonstrates endothelium-dependent microvascular function is 
the microvascular resistance, reported as the index of microvascular resistance (IMR) or the hyperaemic 
microvascular resistance (hMR). Microvascular resistance is measured during a hyperaemic state with either 
intracoronary thermodilution (IMR) or Doppler techniques (hMR) and reflect abnormalities in the function 
and/or structure of the coronary microvasculature. The endothelium-dependent microvascular function can be 
tested with acetylcholine. In healthy endothelium, acetylcholine results in a net vasodilation because its 
stimulation of NO and other vasodilators exceeds its direct vasoconstrictor effects on the VSMCs. In CMD, 
when endothelial function and/or VSCMc function are damaged, NO resources are depleted, and the 
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3. Diabetes mellitus 
Patients with diabetes have a three times higher risk of mortality compared to patients without diabetes.
11, 12
 
Microvascular and macrovascular complications are important determinants of morbidity and mortality in DM. 
Macrovascular complications, including IHD, occur about twice as often in patients with diabetes compared to 
those without, independent from other risk factors.
13
 Microvascular complications, including CMD, are often 
present before the onset of macrovascular complications. Patients with type 1 or type 2 diabetes have a high 
prevalence of CMD,
14-16
 which is a strong predictor of adverse cardiovascular outcome even before 
macrovascular complications are evident.
15, 17
 Diabetic patients with a reduced CFR show mortality rates as 




3.1 Hyperglycaemia and insulin resistance  
Hyperglycaemia and insulin resistance are important factors in the development of CMD in DM.
19
 They induce 
an imbalance between the bioavailability of vasoprotective NO and the accumulation of reactive oxygen 
species (ROS), as illustrated in figure 2.
19, 20
  
Hyperglycaemia induces several events - including the activation of protein kinase C (PKC)
21
 - that lead to the 
generation of ROS (e.g. superoxide anion) and oxidative stress.
22
 ROS leads to uncoupling of the endothelial NO 
synthase (eNOS) and to the production of superoxide anion via increased lipid peroxidation products. 
Superoxide anion reacts with NO to form peroxynitrite, which not only reduces the bioavailability of NO but 
also reduces the NO production and decreases the responsiveness of tissue to NO.
23, 24
 Superoxide anion also 
increases the production of ROS via advanced glycation end products (AGEs) and activation of the receptor for 
AGE (RAGE) on vascular cells.
21
 These processes likely recruit xanthine oxidase, leading to a further increase in 
ROS levels and augmenting oxidative stress.
25
  
Insulin resistance contributes to this detrimental process by decreasing the activity of eNOS and reducing the 
production of NO, resulting in less available vasoprotective NO.
22
 The mainly NO-driven endothelium-
dependent vasoreactivity is related to insulin resistance and has been shown to improve when insulin 
resistance improves using metformin treatment.
26
 The hyperinsulinemia in DM is also associated with elevated 
levels of free fatty acids
27, 28
 that contribute to oxidative stress and a proinflammatory state by activating PKC, 
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3.2 Pro-inflammatory state 
Many of the aforementioned processes contribute to the activation of the endothelium to a pro-inflammatory 
state, resulting in the enhanced endothelial expression of adhesion molecules such as intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, the release of 
proinflammatory cytokines, the migration and proliferation of VSMCs, and an increased synthesis of 
endothelin. Progressive arterial stiffness and a higher pro-thrombotic state further contribute to the 
development of CMD and macrovascular complications in patients with DM.
22, 31-33
 These proinflammatory 





The cycle of inflammation and oxidative stress, does not only affect cardiac cells but also induces cell damage in 
pancreatic beta-cells, further enhancing DM. Treatment should therefore be aimed at managing all factors that 
contribute to this vicious cycle. Glycaemic control is key in diabetics and even little variations in glycaemic state 
are important in maintaining a healthy vascular state.
34, 35
 Long-term aggressive management of co-existing 
traditional cardiovascular risk factors reduces the risk of cardiovascular events in patients with type 2 DM by 
about fifty per cent and should be implemented in the treatment of patients in an early stage.
36-38
 Although we 
await studies to confirm this, we believe that patients with both diabetes and a reduced CFR could benefit even 
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4. Obesity and CMD 
Obesity, defined as body mass index (BMI) 30 kg/m
2
 or higher, is one of the ongoing epidemics in industrialised 
countries. Some obese individuals are at an increased risk of developing cardiovascular events.
39
 The 
mechanisms responsible for increased cardiovascular risk in obesity, however, are complex and may vary in 
different individuals. Increased oxidative stress, low-grade systemic inflammation and increased sympathetic 
nervous system activity have been postulated as risk factors, as they can lead to CMD and reduced coronary 
flow reserve (CFR)
40
, which is, in turn, associated with impaired clinical outcomes including increased 
mortality.
41, 42
 Positron emission tomography (PET) flow studies
43
 carried out in “metabolically healthy” obese 
individuals (i.e. obesity without systemic hypertension, dyslipidaemia or diabetes) have shown CFR 
abnormalities to be present in these persons. Recently, Bajaj et al.
44
 assessed the relationship between body 
mass index (BMI) and CMD, and their possible link with adverse cardiovascular events in patients with and 
without obesity. They found that in obese patients, CFR decreased linearly with increasing BMI and was 
independently associated with cardiovascular events. In obese patients, individuals with impaired CFR showed 
a higher adjusted rate of cardiovascular events (5.7% vs. 2.6%; p = 0.002).
44
 CMD was independently associated 
with elevated BMI and adverse clinical outcomes. Moreover, CFR was a better marker of risk than both BMI 
and conventional cardiovascular risk factors. This was a retrospective study involving 827 subjects undergoing 




rubidium PET. Clinical endpoints defined as 
a composite of death or nonfatal myocardial infarction or heart failure were assessed during follow-up (median 
follow-up 5.6 years). In the Bajaj study
44
, BMI and CFR both were good prognostic markers, but only CFR was 
independently associated with events. Of interest, only obese patients with reduced CFR - particularly those 
with a very high BMI (30 to 39 kg/m
2
) - had increased cardiovascular risk, i.e. ≥ 2.5-fold increased rate of 
events. An impairment of the vasodilatory capacity of the coronary circulation has been shown to precede the 




In obese patients, there is growing evidence of the association among increased BMI, metabolic abnormalities, 
and systemic inflammation, probably as a result of the actions of adipocytokines such as leptin, adiponectin, 
interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-α) on microvascular function
40
 suggesting a 
pathogenic link between obesity and CMD. Current and previous research
43
 suggest that an imbalance among 
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 The notion that a reduced CFR due to CMD rather than just “obesity”, is associated with 
impaired outcomes in obese patients has pathophysiological and therapeutic importance. Cardiovascular risk 
may vary in different obese individuals and not all may benefit from the same preventative or therapeutic 
measures. Individuals with severe CMD may benefit from treatments addressing the many pathogenic 
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5. Hypertensive pregnancy disorders 
Hypertensive pregnancy disorders (HPD) complicate 5% to 15% of pregnancies. The most severe form of HPD is 
preeclampsia, occurring in 3-5% of all pregnancies.
46, 47
 The International Society for the Study of Hypertension 
(ISSHP) defines preeclampsia as new-onset hypertension after 20 weeks gestation in combination with either 
proteinuria (≥ 300 mg/day) or other maternal dysfunctions, such as renal insufficiency, liver involvement, 
neurological or haematological complications or uteroplacental dysfunction.
48
 Unlike previous beliefs that HPD 
are self-limiting conditions that resolve after delivery of the placenta, we now know that women with HPD 
have an up to 8-fold increased risk of cardiovascular disease (CVD) later in life.
47, 49
 HPD should be regarded as a 
window into future maternal cardiovascular health; evidence points towards a partially shared pathophysiology 
in HPD and CVD.
50
  
A combination of maternal and placental factors is considered to be responsible for the development of HPD, 
in which an increased inflammatory response and maternal (systemic) endothelial dysfunction are key 
features.
51
 In many women with HPD, there is a pre-existing (genetically) increased risk for CVD. Signs of an 
abnormal systemic endothelial function are present even before the onset of preeclampsia, possibly related to 
an already enhanced inflammatory state.
52
 The placenta itself is also important in the pathogenesis of HPD. An 
abnormal placentation in early pregnancy (e.g. abnormal invasion of trophoblasts and inadequate maternal 
spiral artery remodelling) causes placental malperfusion and hypoxia.
53, 54
 This results in oxidative stress, a 
generalized hyperinflammatory state and an exaggerated endothelial activation.
55
 During preeclampsia, several 
markers of inflammation, such as TNF-α, IL-6, IL-17, and vasoconstrictor endothelin 1 (ET-1), are substantially 
increased in the maternal circulation and the placenta.
56
 The hyperinflammatory state and the systemic 
endothelial dysfunction that occur in HPD, seem to persist postpartum, which may underlie the development 
of CVD later in life. Months to years after delivery, affected women remain to have increased plasma 
concentrations of inflammatory markers compared to women who had a normal pregnancy, i.e. higher baseline 
levels of CRP, IL-6 and fibrinogen, 
57
 and alterations in TNF-α, IL-6, leptin, adiponectin, homocysteine, soluble E-
selectin, and pregnancy-associated plasma protein-A (PAPP-A). 
58-62
 An increase in the CRP response to 
vaccination and a consistent pattern of increased acute-phase responses to vaccination for all inflammatory 
markers were also found among women after preeclampsia compared to controls, indicating that vascular 
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5.1 CMD and IHD after preeclampsia 
These altered vascular responses are also observed in the coronary circulation: an impaired CFR and other signs 
of CMD have been shown in women up to several years after preeclampsia compared to women who had a 
healthy pregnancy and delivery (2.39 ± 0.48 vs. 2.90 ± 0.49; p < 0.001).
64, 65
 Although prospective data are 
lacking, many of these women mention MVA in their fifth and sixth decade. An important trigger for MVA in 
these patients is premature hypertension. Premature signs of subclinical CAD have been demonstrated by 
carotid intima-media thickness measurements and coronary artery calcium scores in middle-aged women after 
preeclampsia.
64, 66-68
 This reflects their twofold higher risk to develop IHD.
69
 At an older age, these women may 
develop heart failure with preserved ejection fraction, in relation to their long standing hypertension and 
enhanced inflammatory state. More prospective data are needed to better identify the life-course of women 
after preeclampsia and to determine most optimal strategies for prevention. The primary prevention guidelines 
are currently used for the follow-up of these high-risk women, but secondary prevention guidelines may be 
more appropriate.
70
 In this perspective, it would be interesting to study the benefit of preventive strategies in 
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6. Chronic inflammatory and autoimmune rheumatic disorders 
In recent years it has become apparent that cardiovascular risk is particularly increased in patients with 
inflammatory disorders.
71, 72
 In rheumatoid arthritis (RA), a metanalysis of total of 41 490 cases showed that 
cardiovascular risk was increased by 48%, when compared to individuals without RA (pooled RR 1.48 (95% CI 
1.36 to 1.62)).
73
 Similar observations of increased risk have been made for other autoimmune or inflammatory 
diseases including ankylosing spondylitis (AS)
74
, psoriatic arthritis (PA)
75
 as well as systemic lupus 
erythematosus (SLE).
76
 Experimental studies, which allow to better control study conditions show that this 
increase is in part linked to common cardiovascular risk factors between these comorbidities
77
, but to the large 
extent depend on the role of inflammation as a risk factor of CVD.
78
 Similarly, endothelial dysfunction is a key 
mechanism for both obstructive and non-obstructive forms of CAD, 
79
 linked to both classic cardiovascular risk 
factors and to inflammation.
80
 In large vessels, endothelial dysfunction and stiffening has been widely 





or inflammatory bowel disease.
84
 Microvascular dysfunction has also been widely described in patients with 
inflammatory joint diseases.
85, 86
 A recent metanalysis in 709 patients with rheumatic disease and 650 
controls
87
, showed a significantly reduced CFR in patients with various forms of arthritis. Patients with 
autoimmune disease such as SLE had significantly lower CFR than subjects with mixed 
autoinflammatory/autoimmune disorders, such as RA or PA.
87
 Indeed, recent 5-year follow up study in SLE 
patients showed significant non-obstructive impairment of myocardial perfusion in more than half of the 
patients with SLE.
88
 However, coronary as well as peripheral microvascular dysfunction have been observed 
already in early RA even after 6 months since initial diagnosis
89
 . Several studies have also shown systemic 
microvascular dysfunction as measured in peripheral vascular beds in patients with RA and AS.
72, 90
 Interesting 
insight into the CMD can be gained from the analysis of skin microvasculature, which has been shown to offer a 
useful model to study arteriole function and capillary morphology.
91
 Findings from these studies are in line with 
earlier invasive observations that NO-mediated, acetylcholine-induced vasorelaxation in microvessels is 
impaired in AS and may improve with anti‐TNF-α therapy.
86, 90
 In similarity to large vessel endothelial 
dysfunction, microvascular dysfunction has been identified in a number of inflammatory conditions, such as 
severe chronic periodontitis
92
 or inflammatory bowel disease
93
, where impairment correlates with CRP. Thus, 
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6.1 Mechanisms contributing to CMD in rheumatoid disorders 
Clinical metanalyses of CFR in rheumatic disease do not seem to provide sufficient hints regarding the 
mechanisms that cause CMD. Across over 20 studies in several rheumatic diseases, reductions of CFR were not 
linked with either inflammatory burden, lipids, body mass index, age or even blood pressure.
87
 It is particularly 
surprising that some large studies, such as a longitudinal Dudley Rheumatoid Arthritis Comorbidity Cohort 
(DRACCO) study, did not show any association between cumulative inflammatory burden as measured with 
CRP or erythrocyte sedimentation rate (ESR), and endothelial function after 6 years follow-up.
94
 However, the 
observational nature of this study and the use of solely CRP and ESR to measure inflammation leave the main 
question of the relationship between inflammation and CMD open. In fact, other studies have shown that 
clinical inflammatory burden in patients with AS is associated with microvascular flow impairment.
72
 Notably, 
some interventional evidence shows that anti-inflammatory biological therapies such as anti-TNF treatments 
lead to improvement of coronary and peripheral microvascular dysfunction
90
, although results are often 
conflicting and not emerging from randomized or placebo controlled studies.
72
  
Most preclinical and observational studies point to an important mechanistic importance of systemic 
endothelial dysfunction in rheumatic disease, which seems to coincide with or precede both macro- and micro-
vascular disease/dysfunction.
95
 A schematic overview is provided in figure 3. Systemic endothelial dysfunction 
is linked with increased oxidative stress, possibly upregulation of NADPH oxidases (Nox) as well as vascular 
mitochondrial dysfunction.
7
 Increased ROS production is part of the pathogenesis of arthritis as it is induced in 
endothelial and vascular smooth muscle cells by a number of inflammatory mediators including IL-17, IFN-γ, 
TNF-α.
7







Oxidative stress is reported both locally and systemically in mouse models of RA.
100
 Interestingly there is a two 
way interaction between vascular renin-angiotensin aldosterone (RAAS) system activation, which is closely 
linked to oxidative stress, and disease activity in RA or SLE. Angiotensin receptor blockers inhibit Nox 
expression and activation and have been shown to improve endothelial function in animal models of 
arthritis.
101
 Together, this evidence suggests that oxidative stress may be intrinsically involved in establishing 
and potentiating RA-associated vascular damage both locally and systemically.  
 Mechanistically, the L-arginine analogue asymmetric dimethylarginine (ADMA) has been suggested to 
play a role in with CMD in RA.
72
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competitive inhibition of NOS. However, in further observational studies neither coronary nor skin 
microvascular endothelial function correlated with ADMA.
102
 This might indicate that microvascular dysfunction 
in rheumatic diseases may be less dependent on this mechanism.  
A number of immune cells, specifically those involved in the pathogenesis of arthritis and rheumatic 
disorders, have been implicated in the pathogenesis of endothelial dysfunction and CMD in rheumatic 
disorders as well.
103
 Cell type indicated by clinical studies include T-cells, natural killer (NK) cells and 
monocytes. Notably, immune deficient mice lacking T-cells, B-cells, and NK-cells or mice lacking only T- and B-
cells present smaller diameters of microvasculature (third-order cremaster arterioles). Vasoconstriction of 
these vessels is particularly promoted by NK-cells 
104
 as well as potentially dysregulated CD28null (CD4+ and 
CD8+) that produce proinflammatory cytokines known to induce oxidative stress and endothelial dysfunction 
(interferon-γ, TNF-α, and IL-2) and may also cause arteriolar rarefaction.
105, 106
 These cells are also a hallmark of 
other chronic inflammatory conditions such as periodontitis, and they decrease upon successful intensive 
therapy of periodontitis.
83
 Lymphocyte involvement in the vascular pathology in patients with inflammatory 
disease is closely linked to oxidative stress. For example, Nox2 is expressed by T-cells and antigen presenting 
cells and mediates their activation and ability to serve homeostatic immune functions. 
107, 108
 We have also 
identified that in particular pro-inflammatory monocytes, CD14(high)CD16+ are related to endothelial 
dysfunction in arthritis patients 
109
, while in general CAD population a different subset of monocytes 
(CD14dimCD16+) were primarily correlated.
110
 While a number of cell types may be involved, final effectors of 
this response appear to be linked to overexpressed cytokines. An elegant study by Ahmed et al. has shown that 
in dysfunctional vasculature of patients with RA, a particular overexpression of IL-18, IL-33, and TNF is observed 





Understanding the unique mechanisms of CMD in chronic inflammatory and rheumatic diseases may allow for 
a more specific diagnosis and prevention. In particular understanding the relationship between clinical disease 
severity, inflammatory burden and the development of CVD is essential. Understanding the role of individual 
cell types and cytokines in this process may allow more direct targeting in the future. Statins may represent a 
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mechanisms of microvascular dysfunction. Recently, specific trials of immune-targeted therapies in CVD, 
namely the Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial and the Cardiovascular 
Inflammation Reduction Trial (CIRT) have tested the utility of IL-1β and methotrexate targeting in the 
prevention of major cardiovascular events showing that modes of targeting are essential for outcomes, as 
discussed by us extensively elsewhere.
112
 However, while they provide proof-of concept, lack of focus on CMD 
was present in either of these trials, which makes it difficult to extrapolate their results. It is clear that we 
should diagnose and actively search for CMD in patients with rheumatic inflammatory and autoimmune 
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7. Chronic kidney disease  
Chronic kidney disease (CKD) is a known risk factor for CVD. For a long time, this risk was assumed to be the 
result of the high prevalence of traditional cardiovascular risk factors. Indeed, hypertension and diabetes are 
the main causes of CKD. Also, CKD promotes the development of hypertension by activation of the RAAS 
system, sodium retention and increased concentrations of catecholamines. However, metanalyses have clearly 
shown that an impaired kidney function is a cardiovascular risk factor independently of the presence of other 
traditional cardiovascular risk factors.
113
 Patients with an estimated glomerular filtration rate (eGFR) below 15 
ml/min/1.73m
2
 still have a three times higher risk of cardiovascular death compared to those with a normal 
kidney function, even when adjusted for other risk factors.
114
 The number of deaths from CVD increases as 
eGFR rate decreases.
113
 Besides cardiovascular death, patients with CKD are also at risk for developing CVD, e.g. 
diastolic dysfunction, left ventricular hypertrophy (LVH) or ischemic heart disease, referred to as type 4 
cardiorenal syndrome.
115
 CMD is one of the key features in the pathophysiology of this syndrome. CMD, 
measured as a reduced CFR, is present in many patients with CKD compared to healthy controls.
116, 117
 And, 
concordant with what we have discussed in the other sections of this paper, the CFR is independently 




7.1 The link between CMD and cardiorenal syndrome 
It is assumed that uraemia-specific mechanisms contribute to CMD and CVD in patients with CKD.
120
 It has been 
shown that uraemia promotes microvascular rarefraction.
121
 In post-mortem samples, patients with CKD have 
an almost 50% decrease in capillary density in the heart.
122, 123
 Moreover, uraemia induces a state of oxidative 
stress and an increased inflammatory state by several mechanisms,
124
 an enhanced activity of NAD(P)H 
oxidase,
125
 a reduced bioavailability of NO caused by an increase in the NO-synthase inhibitor ADMA,
123
 and 
increased levels of inflammatory markers (i.e. CRP, TNF-α, IL-1β and IL-6).
126
 As we have discussed before, 
oxidative stress and inflammation link to CMD.  
 
The most common phenotype of the type 4 cardiorenal syndrome is LVH: nearly 75% of adults with end-stage 
renal disease have signs of LVH
127
 and the severity of LVH is an independent predictor for mortality.
128
 Both the 
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cardiomyopathy, including hypertension, increased vascular stiffness, increased levels of steroid hormones, 




It is evident that CKD and CVD enhance each other. Future research should focus on unravelling the causality 
between uraemia-specific mechanisms, CMD and the development of CVD in these patients. These insights 
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8. Hypertrophic cardiomyopathy 
HCM is the most common genetic heart disease, with a prevalence of 1:500 in the general population, and is 
defined by the presence of primary LVH that is not explained by abnormal loading conditions.
131, 132
 Myocardial 
ischaemia often occurs in patients with HCM, even in the absence of clinical symptoms.
133-136
 The substrate for 
myocardial ischaemia are perfusion defects, as represented by a reduced CFR in patients with HCM.
137
 These 
perfusion defects are often subendocardial and are most pronounced in the most hypertrophied (septal) 
segments.
138, 139
 Perfusion abnormalities are associated with the presence of myocardial fibrosis,
139
 and fibrosis 
contributes to life-threatening electrical instability in HCM.
134, 136, 140
  
Even though the assessment of CFR in HCM is not yet incorporated in HCM management guidelines or risk 
algorithms, the presence of CMD can identify patients at risk and those with no signs of CMD seem to have a 
relative good prognosis.
141
 The degree of CMD is a strong and independent predictor of clinical deterioration 
and death.
136, 142
 CMD also predicts long-term adverse LV remodelling and systolic dysfunction, even in patients 
with no or mild symptoms and normal LV function,
141, 142
 making it a potential target for the prevention of 
disease progression in HCM.  
 
8.1 Different mechanisms contribute to CMD in HCM 
CMD is more than just a supply/demand mismatch caused by the overall increase in metabolic demand of the 
increased myocardial mass in patients with HCM. Both structural and functional alterations are important 
factors in CMD and subsequent myocardial ischaemia. Already decades ago, histopathological studies showed 
that HCM patients have markedly abnormal coronary microvasculature structure: the luminal areas of the 
arterioles are severely reduced due to intimal hyperplasia or medial hypertrophy,
134, 143, 144
 and HCM patients 
have a lower number of capillaries and lower capillary density compared to normal controls.
145
 These changes 
are observed in both hypertrophic obstructive cardiomyopathy and end-stage HCM, but myocardial fibrosis is 
more severe in end-stage HCM.
146
 The more functional and dynamic factors associated with CMD in HCM are 
perfusion abnormalities that result from a deranged coronary blood flow throughout both systole and 
diastole.
147
 In the hypertrophied hearts, compression of the intramyocardial arterioles during ventricular 
systole results in less coronary flow, as shown by wave intensity analysis.
147
 This compression causes elevated 
pressures in the microcirculation that can stop or even reverse flow in the epicardial coronary arteries, a 
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obstruction, blood flow is even further decreased during systole. In addition to these derangements during 
systole, there is a decrease in coronary flow during diastole as well, related to an impaired ventricular 
relaxation and increase in passive stiffness.  
 
8.2 Clinical implications 
It is unlikely that treatment will reverse the structural changes in the microvasculature of HCM once they are 
present. However, the presumably preceding dynamic changes, marked by a decreased CFR, could be 
influenced by medical interventions. Septal ablation has been shown to improve CFR and blood flow 
dynamics.
148
 The use of beta-blockers and calcium channel antagonists are interesting in this regard as well, for 
they theoretically increase diastole and decrease the contractile forces that reduce CFR. Whether these 
interventions decrease or prevent subendocardial ischaemia and subsequent fibrosis needs to be studied in 
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9. Aortic valve stenosis  
Another condition that is associated with LVH is aortic valve stenosis (AoS), in which the LVH develops in 
response to pressure overload. Men and women with similar degrees of AoS have different LV adaptations to 
this pressure overload. Women more frequently have a greater degree of LVH, higher relative wall thickness, 
smaller end-systolic and end-diastolic chamber size.
149
 The development of LVH is accompanied by the 
development of CMD in AoS.
150, 151
 As we have learned in the previous paragraph of this manuscript, LVH is 
associated with a functionally deranged coronary blood flow, while oxygen demands increase,
152
 causing 
cardiac ischaemia. Related to the pressure drop across the aortic valve, there is less systolic acceleration of 
coronary blood flow in patients with AoS compared to healthy controls.
153
 In addition to this, coronary arteries 
are compressed to a larger extent in the hypertrophied and pressure-overloaded left ventricle during 
isovolumetric contraction when the aortic valve is still closed, causing a decrease of coronary blood flow in this 
period of the heart cycle.
154
 A reduced diastolic perfusion time during exercise and a high diastolic wall stress 
add to this blood flow maldistribution during exercise or hyperaemia, resulting in a decreased CFR and 
subendocardial myocardial ischaemia during stress.
150
related more to the severity of AS (valve effective orifice 
area) , hemodynamic load and reduced diastolic perfusion time rather than to the increase in LV mass.  
 
Studies have even shown that the reduced CFR in AoS is more related to the severity of AoS (i.e. the valve 
effective orifice area),
155
 hemodynamic load, and reduced diastolic perfusion time than it is to the increase in 
LV mass.
150
 In line with this observation is the direct improvement of the CFR after successfully treatment of AS 
is with a transcatheter aortic valve replacement (TAVR): immediately after TAVR baseline haemodynamics 
remain unchanged whereas hyperaemic parameters are improved , if there is no important aortic 
regurgitation.
156
 Unlike in HCM, the coronary microvasculature of patients with severe AoS show no signs of 
intramural medial hypertrophy, making it unlikely that structural changes of the microvasculature contribute 
significantly to CMD in patients with AoS.
157
 The presence of CMD is associated with angina but not all patients 
with AoS and angina show signs of CMD.
158, 159
 CMD could however play a significant pathophysiological role in 
the natural history of AoS contributing to the development of cardiac fibrosis and LV dysfunction. CFR was 
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In the treatment of patients with AoS, it has been shown beneficial to focus on the mechanisms involved in the 
dynamic alterations in coronary flow that are associated with CMD and myocardial ischaemia, such as the short 
diastolic time. A propensity-matched post-hoc analysis showed that betablocker use reduces all-cause 
mortality (hazard ratio 0.5, 95% confidence interval 0.3-0.7, P<0.001), cardiovascular death (hazard ratio 0.4, 
95% confidence interval 0.2-0.7, P<0.001), and sudden cardiac death (hazard ratio 0.2, 95% confidence interval 
0.1-0.6, P=0.004) in 1873 asymptomatic patients with mild to moderate AoS and preserved left ventricular 
ejection fraction.
161
 The ultimate treatment of severe symptomatic AS is aortic valve replacement. It would be 
interesting to study if CMD could aid in choosing the optimal timing of this intervention, before extensive 
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10. Summary and future perspectives 
CMD can occur in the setting of a wide variety of cardiac and systemic clinical conditions, and often results 
from changes in microvascular structure, microvascular function and/or a maldistribution of coronary blood 
flow. Despite the various mechanisms involved in the presence of CMD in the discussed clinical conditions, 
CMD is consistently associated with myocardial ischaemia and portrays an increased risk for cardiovascular 
events. CMD is often detectable very early in the course of the primary disease, before clinical symptoms or 
signs of myocardial ischaemia are present. These observations support the potential use of CMD in strategies 
for risk stratification, which should be explored further. Novel agents that target specific pathways that lead to 
endothelial damage and a pro-inflammatory state are an active area of research at present and could provide 
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14. Figure legends 
Legend to figure 1: different factors involved in coronary microvascular dysfunction 
Dynamic, structural factors, and functional factors contribute to the occurrence of coronary microvascular 
dysfunction the presence of other conditions. Endothelial dysfunction and vascular smooth muscle cell 
dysfunction are caused by (often a combination of) structural and/or functional factors. VSMC = vascular 
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Legend to figure 2: Schematic overview of the pathophysiological mechanisms of coronary microvascular 
dysfunction in diabetes.  
Both hyperglycaemia and insulin resistance contribute to oxidative stress, the release of pro-inflammatory 
cytokines and the decrease of the nitric oxide availability. LDL = low-density lipoprotein, Ox-LDL = oxidized LDL, 
VCAM-1 = vascular cell adhesion molecule-1, ICAM-1 = , E-selectin = , eNOS = endothelial nitric oxide synthase, 
PKC = protein kinase C, NO = nitric oxide, ILs = interleukins, cGMP = cyclic guanosine monophosphate, TNF-α = 





Legend to figure 3: Schematic overview of the mechanisms involved in the systemic endothelial dysfunction that 
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SLE = systemic lupus erythematosus, PA = psoriatic arthritis, RA = rheumatic arthritis, SS = systemic sclerosis, 
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